Last reviewed · How we verify
Treatment regimens for MDR-TB
MDR-TB treatment regimens combine multiple anti-tuberculous drugs to overcome drug resistance and eliminate Mycobacterium tuberculosis.
MDR-TB treatment regimens combine multiple anti-tuberculous drugs to overcome drug resistance and eliminate Mycobacterium tuberculosis. Used for Multi-drug resistant tuberculosis (MDR-TB).
At a glance
| Generic name | Treatment regimens for MDR-TB |
|---|---|
| Also known as | Treatment regimen for MDR-TB using WHO guidelines |
| Sponsor | Shanghai Pulmonary Hospital, Shanghai, China |
| Drug class | Anti-tuberculous combination therapy |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Multi-drug resistant tuberculosis (MDR-TB) requires combination therapy using second-line agents such as fluoroquinolones, injectable aminoglycosides, and other drugs that target different bacterial pathways. These regimens are designed to prevent further resistance development and achieve bacterial clearance in patients whose infections are resistant to first-line TB drugs (isoniazid and rifampicin).
Approved indications
- Multi-drug resistant tuberculosis (MDR-TB)
Common side effects
- Ototoxicity (hearing loss)
- Nephrotoxicity
- Peripheral neuropathy
- Hepatotoxicity
- Gastrointestinal disturbances
- Arthralgia
Key clinical trials
- Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis (PHASE1)
- Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance
- Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment (PHASE4)
- Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB (PHASE2)
- A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis (PHASE3)
- Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) (PHASE2)
- Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis (PHASE2, PHASE3)
- A Study on the Short - Course Treatment Regimen Containing Pretomanid for Diabetes Mellitus Complicated With Rifampicin - Resistant/Multidrug - Resistant Pulmonary Tuberculosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: